FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1818742712> ?p ?o ?g. }

• W1818742712 abstract "BACKGROUND In people with sickle cell disease, sickled red blood cells cause the occlusion of small blood vessels which presents as episodes of severe pain known as pain crises or vaso-occlusive crises. The pain can occur in the bones, chest, or other parts of the body, and may last several hours to days. Pain relief during crises includes both pharmacologic and non-pharmacologic treatments. The efficacy of inhaled nitric oxide in pain crises has been a controversial issue and hypotheses have been made suggesting a beneficial response due to its vasodilator properties. Yet no conclusive evidence has been presented.This review aims to evaluate the available randomised controlled studies which address this topic. OBJECTIVES To capture the available body of evidence evaluating the efficacy and safety of the use of inhaled nitric oxide in treating pain crises in people with sickle cell disease; and to assess the treatment's relevance, robustness, and validity, in order to better guide medical practice in the fields of haematology and palliative care (since recent literature seems to favour the involvement of palliative care for those people). SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register. Unpublished work is identified by searching the abstract books of the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting.Date of most recent search: 19 September 2019.We also searched ongoing study registries, date of most recent search: 26 September 2019. SELECTION CRITERIA Randomised and quasi-randomised trials comparing inhaled nitric oxide with placebo, or standardized way of treatment of pain crises in people with sickle cell disease. DATA COLLECTION AND ANALYSIS Two authors independently assessed trial quality and extracted data (including adverse event data). A third author helped clarify any disagreement. When the data were not reported in the text, we attempted to extract the data from any table or figure available. We contacted trial authors for additional information. We assessed the quality of the evidence using the GRADE criteria MAIN RESULTS: We identified six trials, three of which (188 participants) were eligible for inclusion in the review. There were equal numbers of males and females; and most participants were adults, although one small trial was conducted in a children's hospital and recruited children over the age of 10 years. All three parallel trials compared inhaled nitric oxygen (80 ppm) to placebo (room air) for four hours; one trial continued administering nitric oxide (40 ppm) for a further four hours. This extended trial had an overall low risk of bias; however, in the remaining two trials we had concerns about the risk of bias from the small sample size and additionally a high risk of bias due to financial conflicts of interest in one of these smaller trials. We were only able to analyse some limited data from the eight-hour trial and report the remaining results narratively.The time to pain resolution was only reported in one trial (150 participants), showing there may be little or no difference between the two groups: with inhaled nitric oxide median 73.0 hours (95% confidence interval (CI) 46.0 to 91.0) and with placebo median 65.5 hours (95% CI 48.1 to 84.0) (low-quality evidence). No trial reported on the duration of the initial pain crisis. Only one large trial reported on the frequency of pain crises in the follow-up period and found there may be little or no difference between the inhaled nitric oxide and placebo groups for a return to the ED, risk ratio 0.73 (95% CI 0.31 to 1.71) or for re-hospitalisation, risk ratio 0.53 (95% CI 0.25 to 1.11) (150 participants; low-quality evidence).There may be little or no difference between treatment and placebo in terms of reduction in pain score at any time point up to eight hours (150 participants). The two smaller trials reported a beneficial effect of inhaled nitric oxide in reducing the visual analogue pain score after four hours of the intervention, but these trials were small and limited compared to the first trial.Analgesic use was reported not to differ greatly between the inhaled nitric oxide group and placebo group in any of the three trials, but no analysable data were provided. The median duration of hospitalisation was reported by two trials, in the largest trial the placebo group had the shorter duration and in the second smaller (paediatric) trial hospitalisation was shorter in the treatment group.Only the largest trial (150 participants) reported serious adverse events, with no increase in the inhaled nitric oxide group during or after the intervention compared to the control group (acute chest syndrome occurred in 5 out of 75 participants from each group, pyrexia in 1 out of 75 participants from each group, dysphagia and a drop in haemoglobin were each reported in 1 out of 75 participants in the inhaled nitric oxide group, but not in the placebo group) (low-quality evidence). AUTHORS' CONCLUSIONS The currently available trials do not provide sufficient evidence to determine the effects (benefits or harms) of using inhaled nitric oxide to treat pain (vaso-occlusive) crises in people with sickle cell disease. Large-scale, long-term trials are needed to provide more robust data in this area. Patient-important outcomes (e.g. measures of pain and time to pain resolution and amounts of analgesics used), as well as use of healthcare services should be measured and reported in a standardized form." @default.
• W1818742712 created "2016-06-24" @default.
• W1818742712 creator A5009474972 @default.
• W1818742712 creator A5050312853 @default.
• W1818742712 creator A5057582041 @default.
• W1818742712 creator A5083697788 @default.
• W1818742712 date "2015-07-22" @default.
• W1818742712 modified "2023-10-05" @default.
• W1818742712 title "Inhaled nitric oxide for treating pain crises in people with sickle cell disease" @default.
• W1818742712 cites W170006779 @default.
• W1818742712 cites W1825800091 @default.
• W1818742712 cites W1873662028 @default.
• W1818742712 cites W1974649841 @default.
• W1818742712 cites W1975916217 @default.
• W1818742712 cites W1977185679 @default.
• W1818742712 cites W1978040764 @default.
• W1818742712 cites W1978485157 @default.
• W1818742712 cites W1987410396 @default.
• W1818742712 cites W1999968994 @default.
• W1818742712 cites W2000075945 @default.
• W1818742712 cites W2039508419 @default.
• W1818742712 cites W2043340279 @default.
• W1818742712 cites W2046500825 @default.
• W1818742712 cites W2058874144 @default.
• W1818742712 cites W2070788492 @default.
• W1818742712 cites W2071437295 @default.
• W1818742712 cites W2084545751 @default.
• W1818742712 cites W2112051059 @default.
• W1818742712 cites W2115206864 @default.
• W1818742712 cites W2125435699 @default.
• W1818742712 cites W2126396294 @default.
• W1818742712 cites W2130235475 @default.
• W1818742712 cites W2136403658 @default.
• W1818742712 cites W2150027863 @default.
• W1818742712 cites W2157823046 @default.
• W1818742712 cites W2163777897 @default.
• W1818742712 cites W2322074970 @default.
• W1818742712 doi "https://doi.org/10.1002/14651858.cd011808" @default.
• W1818742712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6788324" @default.
• W1818742712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31603241" @default.
• W1818742712 hasPublicationYear "2015" @default.
• W1818742712 type Work @default.
• W1818742712 sameAs 1818742712 @default.
• W1818742712 citedByCount "3" @default.
• W1818742712 countsByYear W18187427122021 @default.
• W1818742712 crossrefType "journal-article" @default.
• W1818742712 hasAuthorship W1818742712A5009474972 @default.
• W1818742712 hasAuthorship W1818742712A5050312853 @default.
• W1818742712 hasAuthorship W1818742712A5057582041 @default.
• W1818742712 hasAuthorship W1818742712A5083697788 @default.
• W1818742712 hasConcept C126322002 @default.
• W1818742712 hasConcept C159110408 @default.
• W1818742712 hasConcept C177713679 @default.
• W1818742712 hasConcept C1862650 @default.
• W1818742712 hasConcept C194409129 @default.
• W1818742712 hasConcept C2779134260 @default.
• W1818742712 hasConcept C2994186709 @default.
• W1818742712 hasConcept C535046627 @default.
• W1818742712 hasConcept C71924100 @default.
• W1818742712 hasConceptScore W1818742712C126322002 @default.
• W1818742712 hasConceptScore W1818742712C159110408 @default.
• W1818742712 hasConceptScore W1818742712C177713679 @default.
• W1818742712 hasConceptScore W1818742712C1862650 @default.
• W1818742712 hasConceptScore W1818742712C194409129 @default.
• W1818742712 hasConceptScore W1818742712C2779134260 @default.
• W1818742712 hasConceptScore W1818742712C2994186709 @default.
• W1818742712 hasConceptScore W1818742712C535046627 @default.
• W1818742712 hasConceptScore W1818742712C71924100 @default.
• W1818742712 hasLocation W18187427121 @default.
• W1818742712 hasOpenAccess W1818742712 @default.
• W1818742712 hasPrimaryLocation W18187427121 @default.
• W1818742712 hasRelatedWork W1503115105 @default.
• W1818742712 hasRelatedWork W1641007866 @default.
• W1818742712 hasRelatedWork W1694807285 @default.
• W1818742712 hasRelatedWork W1881669862 @default.
• W1818742712 hasRelatedWork W1903436311 @default.
• W1818742712 hasRelatedWork W1931521005 @default.
• W1818742712 hasRelatedWork W1995073473 @default.
• W1818742712 hasRelatedWork W2016308429 @default.
• W1818742712 hasRelatedWork W2025600889 @default.
• W1818742712 hasRelatedWork W2084559222 @default.
• W1818742712 hasRelatedWork W2601282333 @default.
• W1818742712 hasRelatedWork W2609342591 @default.
• W1818742712 hasRelatedWork W2609628334 @default.
• W1818742712 hasRelatedWork W2612549452 @default.
• W1818742712 hasRelatedWork W2754782788 @default.
• W1818742712 hasRelatedWork W2793085333 @default.
• W1818742712 hasRelatedWork W2809142092 @default.
• W1818742712 hasRelatedWork W3021526697 @default.
• W1818742712 hasRelatedWork W3208488873 @default.
• W1818742712 hasRelatedWork W3214300559 @default.
• W1818742712 isParatext "false" @default.
• W1818742712 isRetracted "false" @default.
• W1818742712 magId "1818742712" @default.
• W1818742712 workType "article" @default.